Cornell scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal ...
Cornell scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive ...
Hosted on MSN
ProPhase Labs signals $50M net collection target and strategic initiatives as Crown Medical litigation advances
Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call ...
Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We’re ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Cornell University scientists have taken a major step toward developing a safe, reversible, long-acting and 100% effective nonhormonal male contraceptive, considered the holy grail of male ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results